Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus + Docetaxel in CRPC (CEPTAS)
NCT01206036Phase 2Completed
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Jul 2010
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temsirolimus in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by Central European Society for Anticancer Drug Research. Primary endpoints: Recommended Dose at 10 months and Disease Progression-Free Survival at 24 months. Started Jul 2010; status: completed.
02
Drugs
temsirolimus
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01206036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206036.